Evaluation of Mortality in Users of Pimavanserin Compared with Other Atypical Antipsychotics in Patients with Parkinson’s Disease Psychosis: An Update
In the overall PDP cohort, mortality risk was lower among pimavanserin initiators than comparator antipsychotic initiators.
Authors
- Lisa J. McQuay (ORCID: https://orcid.org/0000-0001-8842-9431)
- Sapna Rao (ORCID: https://orcid.org/0000-0003-4868-6788)
- J. Bradley Layton (ORCID: https://orcid.org/0000-0003-0994-5820)
- Joan Forns (ORCID: https://orcid.org/0000-0002-1066-0358)
- Rebecca E. MacKay (ORCID: https://orcid.org/0009-0006-0042-6599)
- Victor Abler
- Dilesh Doshi (ORCID: https://orcid.org/0009-0006-0970-2158)
- Heather E. Danysh (ORCID: https://orcid.org/0000-0003-3014-7508)
- Marcella A. Anthony (ORCID: https://orcid.org/0000-0002-5760-6965)
Institutions
- Acadia Pharmaceuticals (United States) (US)
- RTI Health Solutions (US)
Publication Details
- Journal
- Drug Safety
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1007/s40264-025-01543-8
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- ACADIA Pharmaceuticals